Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第2页

Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States. 美国2019冠状病毒病大流行期间糖尿病医疗保健可及性和结果的糖尿病差异

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-28 DOI: 10.1080/14737167.2025.2455383

Lixian Zhong, Yanlei Ma, Yelena Ionova, Anjali Bhatt, Ruben Vargas, Timothy Banh, Leslie Wilson

{"title":"Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States.","authors":"Lixian Zhong, Yanlei Ma, Yelena Ionova, Anjali Bhatt, Ruben Vargas, Timothy Banh, Leslie Wilson","doi":"10.1080/14737167.2025.2455383","DOIUrl":"10.1080/14737167.2025.2455383","url":null,"abstract":"Objectives: To investigate the impact of COVID-19 on hospitalization and consequent diabetes-related complications in patients with type 2 diabetes mellitus (diabetes).Methods: We conducted a retrospective cohort study of patients with diabetes. Interrupted time series analysis (ITS) was used to analyze the monthly trends in diabetes-related hospitalization rates, including short- and long-term complications, 1-year before and after onset of COVID-19.Results: Persons with diabetes experienced a significant (p < 0.001) rapid drop in monthly hospital admission rates at onset of COVID-19, then rose significantly (p = 0.003) to higher than pre-COVID-19 levels. Older age, lower education, and income levels were associated with higher base-level monthly hospital admission rates and a greater rate reduction at COVID-19 onset. ITS analysis showed monthly hospital admission rates from short-term complications surged to higher level 6 months after COVID-19 onset. Hospital admissions due to long-term complications decreased immediately post-COVID-19, but rose significantly (p < 0.001) to higher than pre-COVID levels, with patients experiencing higher nephropathy, angiography, and dermatological complications post-COVID-19.Conclusion: COVID-19 had a negative impact on diabetes-related hospitalization access, resulting in increased short- and long-term complications. Long-term effects of deferred care due to COVID-19 on diabetes-related complications may persist, emphasizing the need for continued education toward improved diabetes self-management.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"623-633"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Lebanese health economic evaluation guideline. 黎巴嫩卫生经济评价准则。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-15 DOI: 10.1080/14737167.2025.2450322

Caroline Daccache, Rana Rizk, Mickaël Hiligsmann, Silvia M A A Evers, Rita Karam

{"title":"The Lebanese health economic evaluation guideline.","authors":"Caroline Daccache, Rana Rizk, Mickaël Hiligsmann, Silvia M A A Evers, Rita Karam","doi":"10.1080/14737167.2025.2450322","DOIUrl":"10.1080/14737167.2025.2450322","url":null,"abstract":"Background: Economic evaluation guidelines (EEGs) serve as a valuable tool to assist appraisers in making consistent and transparent recommendations, standardize EE studies, enhance their quality, and minimize methodological uncertainties. As other LMICs, Lebanon aims for UHC where EEG is a necessity. This paper aims to report on the Lebanese health EEG (LEEG) and its reference case, including the intermediate results leading to the final decisions.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬.Research design and methods: The LEEG followed a structured, systematic, and transparent process: (1) identifying the rationale and the guideline scope; (2) establishing the Guideline Development Group; (3) searching the evidence; (4) planning the development process; (5) selecting the panel for the deliberative process; (6) surveying Lebanese stakeholders; (7) deliberating on the results; (8) drafting the guideline; and (9) consulting with international experts.Results: The LEEG includes three general characteristics, 19 key features, a reference case, and an action plan.Conclusions: The LEEG is the first national EEG for health interventions. It will help decision-makers, researchers, and healthcare providers improve the quality and assessment of EE in Lebanon to identify the most cost-effective health interventions. Implementing LEEG is crucial to promoting an equitable, efficient, and high-quality health system with a more consistent decision-making process.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"551-565"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England's National Institute of Health and Care Excellence. 先进治疗药物产品的价值属性：在英国国家健康和护理卓越研究所报销决策期间收到的利益相关者评论的文献分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-19 DOI: 10.1080/14737167.2025.2455405

Nermina Ferizovic, Ruth Plackett, Caroline S Clarke, Rachael Hunter, Nick Freemantle

{"title":"Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England's National Institute of Health and Care Excellence.","authors":"Nermina Ferizovic, Ruth Plackett, Caroline S Clarke, Rachael Hunter, Nick Freemantle","doi":"10.1080/14737167.2025.2455405","DOIUrl":"10.1080/14737167.2025.2455405","url":null,"abstract":"Objectives: Advanced therapy medicinal products (ATMPs) are transformative healthcare interventions, however, there has been limited research exploring their value. The objective of this study was to conduct a thematic analysis as part of a documentary analysis to identify value attributes of ATMPs.Methods: As part of the NICE assessment processes in England, stakeholders are invited to provide comments on the technology. Nineteen NICE technology assessments (TAs) related to ATMPs were identified and subsequently included in a thematic analysis. All codes (and themes) were generated inductively from the text to reduce bias.Results: This study found that the attributes of value of ATMPs can be categorized into three themes: treatment factors, innovation factors, and wider factors. That is, attributes of value of these interventions include not only direct treatment factors, although this was the largest category, but also additional factors such as those related to innovation and wider impacts the intervention may have, beyond the patient receiving therapy.Conclusions: This thematic analysis of stakeholder comments submitted to NICE as part of TAs for ATMPs enhances the understanding of attributes of value of ATMPs. The findings are applicable to a wider geography.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"605-621"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets. 子宫颈癌的社会经济负担及其对实现世卫组织消除目标所需战略的影响。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-15 DOI: 10.1080/14737167.2025.2451732

Julia M L Brotherton, Claire M Vajdic, Claire Nightingale

{"title":"The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets.","authors":"Julia M L Brotherton, Claire M Vajdic, Claire Nightingale","doi":"10.1080/14737167.2025.2451732","DOIUrl":"10.1080/14737167.2025.2451732","url":null,"abstract":"Introduction: Cervical cancer is almost entirely preventable by vaccination and screening. Population-based vaccination and screening programs are effective and cost effective, but millions of people do not have access to these programs, causing immense suffering. The WHO Global Strategy for the elimination of cervical cancer as a public health problem calls for countries to meet ambitious vaccination, screening, and treatment targets.Areas covered: Epidemiological evidence indicates marked socioeconomic gradients in the burden of cervical cancer and vaccination, screening, and treatment coverage. The unacceptable socioeconomic burden of cervical cancer is largely a function of inequitable access to these programs. We discuss these inequities, and highlight strategies enabled by new evidence and technology. Single dose HPV vaccination, HPV-based screening, and the rapidly moving technology landscape have enabled task-shifting, innovation in service delivery and the possibility of scale. Equitable access to optimal care for the treatment of invasive cancers remains a challenge.Expert opinion: Cervical cancer can be eliminated equitably. It will require global political will, sustained public and private investment, and community leadership to safely and sustainably embed proven tools, technology and infrastructure in local health and knowledge systems.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"487-506"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy. 意大利遗传性甲状腺转蛋白淀粉样变合并多神经病变患者现实世界护理途径的回顾性观察分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-14 DOI: 10.1080/14737167.2025.2450310

Silvia Calabria, Giulia Ronconi, Letizia Dondi, Leonardo Dondi, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Marco Gnesi, Nicola Cosentino, Marco D'Amelio, Nello Martini, Aldo Pietro Maggioni

{"title":"A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy.","authors":"Silvia Calabria, Giulia Ronconi, Letizia Dondi, Leonardo Dondi, Irene Dell'Anno, Carlo Piccinni, Immacolata Esposito, Alice Addesi, Marco Gnesi, Nicola Cosentino, Marco D'Amelio, Nello Martini, Aldo Pietro Maggioni","doi":"10.1080/14737167.2025.2450310","DOIUrl":"10.1080/14737167.2025.2450310","url":null,"abstract":"Background: This retrospective observational study described the epidemiology and the burden on the Italian healthcare service (SSN) of patients with polyneuropathy (PN) associated with hereditary transthyretin amyloidosis (ATTRv).Research design and methods: From the Fondazione ReS (Ricerca e Salute) administrative healthcare database (~5.5 million inhabitants in 2021), patients were identified as having ATTRv-PN in 2021 if they had received treatments for ATTRv-PN under SSN reimbursement (i.e. tafamidis, patisiran, or inotersen) from 1 January 2014 to 31 December 2021 (index date in 2021). Demographics and comorbidities at the baseline, healthcare resource consumption, and related direct costs reimbursed by the SSN throughout the one-year follow-up were described.Results: In 2021, 36 patients with ATTRv-PN (prevalence: 7.4/1,000,000) were identified (males were 83.3%; patients with ≥2 comorbidities were 61.1%; the mean age was 73 ± 8 years). During follow-up, of patients, 91.7% received drugs for ATTRv-PN; >50% received antiepileptics and acid suppressants; 22.2% were admitted to overnight hospitalizations; 30.6% accessed the emergency department; 97.2% received local outpatient specialist care. The per patient mean annual cost was € 122,017; drugs for ATTRv-PN accounted for 94.7% of the total expenditure.Conclusions: This study of real-world patients with ATTRv-PN showed a high rate of comorbidities, and substantial direct healthcare and economic burdens on the SSN.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"535-542"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost effectiveness of obstructive sleep apnea therapies: a systematic review and meta-analysis of cost utility studies. 阻塞性睡眠呼吸暂停治疗的成本效益：成本效用研究的系统回顾和荟萃分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-12 DOI: 10.1080/14737167.2025.2451733

S Sajith Kumar, G Suchitra Lakshmi, Aamir Sohail, Kayala Venkata Jagadeesh, Bhavani Shankara Bagepally

{"title":"Cost effectiveness of obstructive sleep apnea therapies: a systematic review and meta-analysis of cost utility studies.","authors":"S Sajith Kumar, G Suchitra Lakshmi, Aamir Sohail, Kayala Venkata Jagadeesh, Bhavani Shankara Bagepally","doi":"10.1080/14737167.2025.2451733","DOIUrl":"10.1080/14737167.2025.2451733","url":null,"abstract":"Objectives: Obstructive sleep apnea (OSA) is a sleep-related breathing disorder characterized by recurrent episodes of nocturnal breathing cessation resulting from upper airway collapse. Given the absence of a comprehensive review of the cost-effectiveness of OSA treatments, we undertook an extensive systematic review and meta-analysis to calculate the pooled incremental net benefit (INBp).Methods: A systematic search of PubMed, Embase, Scopus, and Tufts cost-effectiveness analysis registry was conducted. INBp with 95% confidence intervals (CI) was estimated using a random-effects model, and heterogeneity was assessed through the Cochrane-Q test and I2 statistic. Study quality was evaluated using the modified ECOBIAS Checklist, and GRADE framework was applied to assess the certainty of outcomes.Results: Thirty-four studies were included in the systematic review, fifteen qualifying for meta-analysis. CPAP was cost-effective compared to other treatments, with a INBp of $13,024 (95%CI $6,813 to $19,236), and substantial heterogeneity (I2 = 97.48%). Compared to no treatment and oral appliances (OAs), CPAP showed cost-effective INB values of $30,834 ($21,325 to $40,343) and $2,708 ($645 to $4,771) respectively.Conclusion: CPAP is cost effective compared to all treatments collectively, as well as specifically to OAs and no treatment though with low certainty.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"507-515"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment.

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-02-28 DOI: 10.1080/14737167.2025.2450352

Christine Poulos, Tomas Marcek, Phani Chintakayala, Marco Boeri, Amy Francis, Edith Langevin, Tanaz Petigara, Jenny O'Connor, Salome Samant

{"title":"Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment.","authors":"Christine Poulos, Tomas Marcek, Phani Chintakayala, Marco Boeri, Amy Francis, Edith Langevin, Tanaz Petigara, Jenny O'Connor, Salome Samant","doi":"10.1080/14737167.2025.2450352","DOIUrl":"10.1080/14737167.2025.2450352","url":null,"abstract":"Objectives: Given the limited evidence on UK nurses' preferences for pediatric hexavalent vaccines, we aimed to evaluate their preferences for these vaccines' attributes.Methods: In a discrete-choice experiment study, 150 nurses chose between 2 hypothetical pediatric hexavalent vaccines with varying attribute levels (device type, plastic in packaging, time on the market, and time the vaccine can stay safely at room temperature) in a series of choice questions. Using random-parameters logit-model estimates, conditional relative attribute importance (CRAI) and odds ratios (ORs) were calculated.Results: Device type (with associated preparation time and risk of dosage errors) was the most important attribute (CRAI, 61%), followed by years on the market (CRAI, 25%). The odds of choosing a prefilled syringe were nearly 3 times the odds of choosing syringe-and-vial combinations requiring reconstitution (OR, 2.80; 95% confidence interval [CI], 1.93-3.68). Vaccines on the market for < 1 year were less likely to be preferred to vaccines available for > 3 years (OR, 0.66; 95% CI, 0.47-0.84). ORs for time a vaccine can stay at room temperature (3 vs. 6 days) (0.94; 95% CI, 0.71-1.16) and plastic blisters in packaging (1.19; 95% CI, 0.80-1.56) were not significant, indicating that these attributes did not influence choices.Conclusions: In this survey, nurses' preferences were mainly influenced by device type.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"543-550"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in resource allocation of diagnostic tests in Spain. 西班牙诊断测试资源分配的挑战。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-09 DOI: 10.1080/14737167.2025.2451743

Reyes Lorente, Fernando Antonanzas

引用次数: 0

The short-term impact of copayment reductions for government subsidised medicines in Australia. 澳大利亚政府补贴药品的共同支付减少的短期影响。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-12 DOI: 10.1080/14737167.2025.2451140

Mohammad Afshar Ali, Firouzeh Noghrehchi, Christine Y Lu

{"title":"The short-term impact of copayment reductions for government subsidised medicines in Australia.","authors":"Mohammad Afshar Ali, Firouzeh Noghrehchi, Christine Y Lu","doi":"10.1080/14737167.2025.2451140","DOIUrl":"10.1080/14737167.2025.2451140","url":null,"abstract":"Background: This study aims to examine the short-term, population-level effects of the 2023 Australian Pharmaceutical Benefits Scheme (PBS) copayment reduction on prescription volume, patients' out-of-pocket (OOP) expenditure, and government contributions.Research design and methods: We conducted a quasi-experimental study using national data from January 2021 to April 2024. For system-level analysis, we examined all drugs used by general patients, focusing on 252 drugs that were 'above copayment' during 2022-2023. We also performed drug category-specific analyses on six broad groups of drugs. Paired-sample t-tests and segmented regression analyses were used to compare prescription volumes, OOP expenditure, and government contributions before and after the copayment reduction.Results: The copayment reduction was not associated with significant changes in prescription volumes or government contributions for general patients. However, the copayment reduction led to an immediate, but not gradual, decrease in inflation-adjusted OOP expenditure. Specifically, there was a relative reduction of 26.1% at 15 months post-policy for drugs above the general copayment (95% confidence interval (CI): -34.10, -18.10; p-value < 0.001). Similar immediate declines were observed across the six selected drug categories.Conclusions: Further research is needed to assess the longer-term effects of copayment reductions, particularly their impact on medication adherence and overall healthcare costs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"567-576"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics. 质量调整生命年（QALYs）变得更贵了吗？糖尿病治疗的经济评估证据。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-04-01 Epub Date: 2025-01-17 DOI: 10.1080/14737167.2025.2451747

Yawen Jiang, Wenjie Hu, Bingxin Hu, Huiqiao Gu, Yuantian Cui, Xinyu Zhao

{"title":"Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics.","authors":"Yawen Jiang, Wenjie Hu, Bingxin Hu, Huiqiao Gu, Yuantian Cui, Xinyu Zhao","doi":"10.1080/14737167.2025.2451747","DOIUrl":"10.1080/14737167.2025.2451747","url":null,"abstract":"Background: Empirical evidence regarding temporal trends in cost per quality-adjusted life year (QALY) gained remains limited. This study investigates the evolution of cost-effectiveness for diabetes mellitus treatments over time.Research design and methods: We analyzed cost-effectiveness analyses of anti-diabetic pharmaceuticals extracted from the Tufts Medical Center Cost-Effectiveness Analysis Registry (CEAR). Incremental cost-effectiveness ratios (ICERs) were normalized by GDP per capita and categorized into four threshold-based groups. In addition, we examined temporal trends in incremental QALYs. Analyses stratified by Organisation for Economic Co-operation and Development (OECD) membership were also conducted.Results: Among 239 eligible studies, the proportion of highly cost-effective interventions in OECD countries decreased from 62.50% (1999-2005) to 35.48% (2021-2023), while interventions exceeding 3хGDP per capita/QALY increased from 12.50% to 54.84%. This trend was less pronounced in non-OECD countries. Mean incremental QALYs remained stable (range: 0.19-0.47) across periods and between OECD and non-OECD countries, suggesting that rising costs rather than diminishing health benefits drive the declining cost-effectiveness.Conclusions: The cost-effectiveness of anti-diabetic medications has deteriorated substantially over time, particularly in OECD countries, despite stable therapeutic benefits. These findings highlight the need for dynamic approaches to cost-effectiveness thresholds and robust price negotiations to ensure sustainable access to innovative therapies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"597-603"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0